{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric%2FEsophageal+Adenocarcinoma&page=2",
    "query": {
      "condition": "Gastric/Esophageal Adenocarcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric%2FEsophageal+Adenocarcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T15:21:05.625Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00633789",
      "title": "Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non-small Cell Lung Cancer",
        "Transitional Cell Carcinoma",
        "Soft Tissue Sarcoma",
        "Gastric/Esophageal Adenocarcinoma",
        "Pancreatic Cancer Including Ampulla of Vater"
      ],
      "interventions": [
        {
          "name": "brivanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 597,
      "start_date": "2008-06",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2015-10-09",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00633789"
    },
    {
      "nct_id": "NCT03365791",
      "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Gastric Adenocarcinoma",
        "Esophageal Adenocarcinoma",
        "Castration Resistant Prostate Adenocarcinoma",
        "Soft Tissue Sarcoma",
        "Ovarian Adenocarcinoma",
        "Advanced Well-differentiated Neuroendocrine Tumors",
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "PDR001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LAG525",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2018-01-24",
      "completion_date": "2020-09-17",
      "has_results": true,
      "last_update_posted_date": "2022-05-27",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 20,
      "location_summary": "San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03365791"
    },
    {
      "nct_id": "NCT02013154",
      "title": "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Neoplasms",
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Gastroesophageal Cancer",
        "Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "DKN-01 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "DKN-01 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leap Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2014-05-05",
      "completion_date": "2021-01-11",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013154"
    },
    {
      "nct_id": "NCT00252889",
      "title": "Doxil Topotecan Doublet Cancer Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Pancreatic Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Topotecan and pegylated doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christiana Care Health Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2004-05",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2009-01-27",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 1,
      "location_summary": "Newark, Delaware",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00252889"
    },
    {
      "nct_id": "NCT04060342",
      "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Esophageal Adenocarcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Triple Negative Breast Cancer",
        "Castration-resistant Prostate Cancer",
        "Microsatellite Stable Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "GB1275",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel and gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2019-08-13",
      "completion_date": "2022-04-11",
      "has_results": false,
      "last_update_posted_date": "2022-08-18",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060342"
    },
    {
      "nct_id": "NCT03141034",
      "title": "Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastro-esophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Blood for angiome profiling",
          "type": "GENETIC"
        },
        {
          "name": "Blood for cfDNA",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2017-11-01",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Tampa, Florida • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03141034"
    },
    {
      "nct_id": "NCT07392892",
      "title": "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma",
        "Metastatic Gastric Cancer",
        "Gastroesophageal Junction Cancer",
        "Esophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "PF-08634404",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 840,
      "start_date": "2026-04-28",
      "completion_date": "2032-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 56,
      "location_summary": "Aurora, Colorado • Boulder, Colorado • Centennial, Colorado + 47 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07392892"
    },
    {
      "nct_id": "NCT01585987",
      "title": "An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Best Supportive care (BSC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2012-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-05-17",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 4,
      "location_summary": "Miami Beach, Florida • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01585987"
    },
    {
      "nct_id": "NCT03154190",
      "title": "Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Brain Glioblastoma",
        "Estrogen Receptor Negative",
        "Extensive Stage Small Cell Lung Carcinoma",
        "Head and Neck Carcinoma",
        "HER2/Neu Negative",
        "Hormone-Resistant Prostate Cancer",
        "Limited Stage Small Cell Lung Carcinoma",
        "Myelodysplastic Syndrome",
        "Progesterone Receptor Negative",
        "Progressive Disease",
        "Recurrent Carcinoma",
        "Stage II Pancreatic Cancer",
        "Stage II Rectal Cancer",
        "Stage IIA Pancreatic Cancer",
        "Stage IIA Rectal Cancer",
        "Stage IIB Pancreatic Cancer",
        "Stage IIB Rectal Cancer",
        "Stage IIC Rectal Cancer",
        "Stage III Colon Cancer",
        "Stage III Esophageal Cancer",
        "Stage III Gastric Cancer",
        "Stage III Non-Small Cell Lung Cancer",
        "Stage III Ovarian Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Rectal Cancer",
        "Stage III Skin Melanoma",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Esophageal Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIA Non-Small Cell Lung Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Rectal Cancer",
        "Stage IIIA Skin Melanoma",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Esophageal Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IIIB Non-Small Cell Lung Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Rectal Cancer",
        "Stage IIIB Skin Melanoma",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Esophageal Cancer",
        "Stage IIIC Gastric Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Rectal Cancer",
        "Stage IIIC Skin Melanoma",
        "Stage IV Bladder Cancer",
        "Stage IV Bone Sarcoma",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Esophageal Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Non-Small Cell Lung Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Skin Melanoma",
        "Stage IV Soft Tissue Sarcoma",
        "Stage IVA Bone Sarcoma",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Bone Sarcoma",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2017-08-08",
      "completion_date": "2022-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-24",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 1,
      "location_summary": "Fullerton, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03154190"
    },
    {
      "nct_id": "NCT01757171",
      "title": "Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastroesophageal Adenocarcinoma",
        "Distal Esophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2012-12",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-06-10T15:21:05.625Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01757171"
    }
  ]
}